Adrenal incidentalomas and Acromegaly Flashcards
(32 cards)
Adrenal incidentaloma (AI) (3)
- derivative of more than 1cm found in the adrenal gland incidentally (found by chance)
- most common –> hormone non-secretory adenomas
- goal: differentiate between benign and malignant, evaluate where the tumor is functionally active
Adrenal incidentaloma (AI) -clinical symptoms (5)
- most patients have none
- symptoms of Cushing’s syndrome
- symptoms of Pheochromocytoma
- symptoms of hyperaldosteronism
- symptoms of malignancy
Adrenal incidentaloma (AI)
- physical examination (6)
- radiological examination (1)
- sonoscopy (ultrasound) (2)
Evaluate:
- BP, HR
- waist circumference, assess obesity type
- skin lesions - ecchymoses, stretch marks
- hirsutism, virilization
- muscle strength
- possible changes in appearance - compared with previous pics
- differentiate between adrenal adenoma, carcinoma, pheochromocytoma and metastasis
- sensitivity is lower, inappropriate to differentiate between benign and malignant tumors
Adrenal incidentaloma (AI)
- CT without venous contrast
- CT with venous contrast
- recommended for initial patient examination, diagnosis is based on density.
- adenoma –> density less than 10 HV in non-contrast images and size smaller than 4cm - recommended if tumor density is >10 HV, malignant tumors are usually larger than 4cm
- benign changes –> density less than 80-90 HV
- pheochromocytoma –> density greater than 100 HV
Adrenal incidentaloma (AI)
- MRT
- Adrenal scintigraphy
- effectiveness in differentiating malignant and benign tumors, test of choice for: pregnant women, children patients allergic to contrast agents
- not first choice, not recommend for routine patient
Adrenal incidentaloma (AI)
- Positron emission tomography (PET)
- Aspiration Pussy (AP)
- not recommended for routine examination, useful when CT results with intravenous contrast are questionable or malignancy is suspected in other methods
- not recommended for all patients, useful when suspecting metastases or infection, pheochromocytoma should be ruled out before performing it (life threatening complications)
Adrenal incidentaloma (AI) -Hormonal examination (3)
- should be performed in all patients except when imagining techniques are used to detect a cyst or myelolipoma
- suspected adrenocortical carcinoma –> sex hormones and steroid precursors
- primary aldosteronism –> only hypertension and hypokalemia should be investigated
Suspected hormonal activity –> recommended initial tests
- Pheochromocytoma
- Aldosteroma
- Cortisol secreting tumor
- free metanephrines in blood or fractionated metanephrines in urine
- aldosterone and renin in blood
- 1mg Dexamethasone suppression test
Examination for pheochromocytoma (2)
- should be investigated in all patients with adrenal derivatives
- free blood urinary metanephrine or fractionated urinary metanephrine
Examination for primary hyperaldosteronism
-hypertension and/ or hypokalemia
Examination for subclinical Cushing’s syndrome (SCS) (4)
- 1 mg Dexamethasone suppression sample
- cortisol levels 138 nmol/l (5 ug/dL) confirms the diagnosis
- testing for cortisol in urine is less sensitive and not routinely recommended
- if adrenal metastases are suspected –> test for adrenal insufficiency
Adrenal incidentaloma (AI) -treatment (2)
Surgery
- not recommended for –> asymptomatic, hormonally inactive, unilateral incidental <4cm incidence with benign features
- recommended for –> size >4cm, suspected malignancy, hormone releasing derivatives, if the tumor increased in size
Laparoscopic adrenalectomy vs. Laparotomy
Laparoscopic adrenalectomy - with tumor <6cm
Laparotomy - if >6cm or if malignancy is suspected
Preoperative and postoperative period after detection of Pheochromocytoma
Preoperative
- correct BP - alpha and beta blockers
- correct HR
Postoperative
-glucocorticoid replacement therapy –> surgery for cortical adenoma and if Cushing’s syndrome has been diagnosed before surgery
Acromegaly (5)
- definition
- prevalence
- rare
- increased secretion of growth hormone (GH) or somatotropic hormone (STH)
- patients aged 40-45 years
- often remains undiagnosed
Acromegaly
- etiology
- genetic syndromes associated with it: (2)
- 99% are caused by benign anterior pituitary adenoma
- 95% have benign monoclonal pituitary adenoma developing from somatotropin cells
- McCune-Albright syndrome - multiple fibrous bone dysplasia, early puberty, cafe-au-lait spots
- hyperparathyroidism, neuroendocrine tumors, endocrine and non-endocrine tumors in patients with MEN1
Acromegaly
-pathogenesis (4)
- the release of GH is regulated by the inhibitory effect of somatostatin and the stimulatory hormone
- GH acts on the body through insulin-like growth factors (IGF-1) synthesis
- increased GH secretion –> increased IGF-1 production
- usually hypersecretion from a benign monoclonal pituitary adenoma
Acromegaly
-signs and symptoms (14)
- facial changes and enlargement of limbs
- enlargement of internal organs
- increased sweating
- menstrual disorders
- paresthesia of the extremities
- headache
- fatigue and drowsiness
- galactorrhea
- goiter
- erection disturbances
- ear, nose, throat or dental disease
- thrombosis/ arrhythmias
- arterial hypertension
- carpal tunnel syndrome
Acromegaly
-complications (6)
Endocrine - pituitary failure, diabetes, osteoporosis
Oncological - colon, breast, stomach, prostate cancer
Breathing - upper airway obstruction, pulmonary emphysema, COPD
Cardiovascular - cardiomyopathy, MI, arrhythmias, sudden death
GI - cholelithiasis
Bone changes - bone formation more intense, thickening of bone diaphysis in long bones and widespread joints, spinal enlargement, widespread intervertebral spaces, chest deformities
Acromegaly
-diagnosis (8)
- blood levels of GH and IGF-1
- dynamic glucose tolerance sample (GTM)
- ophthalmologic diagnostics
- MRI (more sensitive), CT
- examination of pituitary function to rule out failure
- a single GH test is not always informative!
- if acromegaly suspected –> IGF-1 should be tested first
- for active acromegaly –> 75g of OGTT remains >1ng/nl –> GH counteracts insulin
Acromegaly
-treatment (3)
- surgical –> first-choice
- medication
- radiation - used after unsuccessful operation, ineffective medical treatment or when the patient is unable to have surgery. 45-50 Gy is given but cause complete pituitary failure
Acromegaly
-medical treatment (only names - 4)
- Somatostatin analogues - ocreotide, lanreotide, pasireotide
- Dopamine receptor agonists (bromocriptine and cabergoline)
- Growth hormone receptor antagonists (pegvisomant)
- Combined treatment - Somatostatin analog 1/month + Pegvisomant weekly
Acromegaly
-Somatostatin analogues (3)
- ocreotide, lanreotide, pasireotide
- when surgical treatment is inappropriate or ineffective
- side effects: nausea, vomiting, abdominal pain/discomfort, diarrhea
Acromegaly
-Dopamine receptor agonists (5)
- bromocriptine and cabergoline
- inhibit GH secretion but efficacy is low
- indirectly inhibits IGF-1 secretion
- quick onset of action, low risk of hypopituitarism, ease of use
- cabergoline is more effective and better tolerated, fewer side effects